This update was written automatically with AI from market data and news wire reports, and published without review by a person.
Key Takeaways
- Cardinal Health (CAH) reported a significant Q1 2027 beat, with Adjusted EPS of $3.26 (vs. $2.93 estimate) and Revenue of $67.5B (vs. $66.71B estimate).
- The company raised its full-year 2027 Adjusted EPS guidance to a range of $12.80 to $13.00, up from the previous range of $12.40 to $12.60.
- Kimberly-Clark (KMB) posted Q3 2026 Net Sales of $4.13B, slightly ahead of estimates, while reaffirming its full-year 2026 standalone outlook following the recent completion of its Kenvue acquisition.
- UK Prime Minister Andy Burnham indicated that the government's ten-year plan for Britain may be delayed into January 2027, pushing back the expected December unveiling.
Cardinal Health Delivers Strong Q1 Performance and Guidance Hike
Cardinal Health (CAH) started its fiscal year 2027 with a robust first quarter, exceeding analyst expectations across all major financial metrics. The healthcare services provider reported Adjusted Operating Income of $1.0B, surpassing the $922.9M consensus, driven by a 17% profit increase in its Pharmaceutical and Specialty Solutions segment. This segment's revenue rose 6% to $62.6B, supported by strong brand and specialty pharmaceutical sales.
The company's positive momentum led management to raise the FY 2027 Adjusted EPS outlook to $12.80–$13.00, representing a midpoint of $12.90. CEO Jason Hollar attributed the results to consistent execution against strategic priorities and disciplined operations. Additionally, Cardinal Health solidified its long-term outlook by entering a binding letter of intent to extend its distribution agreement with CVS Health through 2032.
Kimberly-Clark Reaffirms Outlook Amid Kenvue Integration
Kimberly-Clark (KMB) reported its third-quarter 2026 results, highlighted by Net Sales of $4.13B and an Adjusted EPS of $1.70. While Adjusted Operating Profit of $677.0M came in slightly below the $690.7M estimate, the company reaffirmed its full-year 2026 standalone outlook. The quarter was marked by the successful completion of the $49 billion Kenvue acquisition on November 2, a move intended to position the company as a leader in global consumer health.
Despite the acquisition, the company noted that organic sales fell 1.3% during the quarter, reflecting a challenging macroeconomic environment. Management continues to focus on margin and cost discipline to carry the earnings line while navigating the integration of Kenvue's portfolio. Investors are closely watching for synergy targets and organizational updates as the combined entity moves into 2027.
UK Policy Delays: Burnham's 10-Year Plan Pushed to 2027
In political developments, UK Prime Minister Andy Burnham has suggested that his administration's flagship ten-year plan could be delayed until January 2027. Originally expected in December, the plan is intended to outline structural reforms in housing, energy, and regional devolution. Burnham stated that the government may need to "leave that open" to ensure the strategy is fully fleshed out before its public debut.
This potential delay follows a "play-safe" budget from Chancellor John Healey, which many analysts viewed as a placeholder until the full ten-year strategy and subsequent spending reviews are finalized. The delay has sparked criticism from political opponents who argue the administration is "parking big decisions" amid rising economic pressures and international security concerns.
Automated market updates written with AI from market data and news wire reports, published without human review.